nd.gov - The Official Portal for North Dakota State Government
North Dakota: Legendary. Follow the trail of legends
Workforce Safety & Insurance Logo Top of the page place holder

Contact Us       About Us       News       Careers       Calendar       Free e-Newsletter       RFI/RFP       Links       Site Map      
spacer image
gray hexagon imagespacer imageForms/Library 
red hexagon imagespacer imageEmployers 
orange hexagon imagespacer imageWorkers 
yellow hexagon imagespacer imageMedical Providers  green hexagon imagespacer imageSafety & Loss Control 
purple hexagon imagespacer imageOnline Services 
tan hexagon imagespacer imageFraud Awareness 
spacer imageHOME 

Good Morning
4:59:49 AM CDT
Tuesday, June 30, 2015

spacer image
ProviderNews left Header ProviderNews right Header
Pharmacy News
January 2015
Prior Authorization Required for Long-Acting Opioid Medication

Effective February 1, 2015, WSI will require prior authorization of long-acting opioid medication.

October 2013
New Pharmacy Benefit Management Company Effective November 1, 2013

On November 1, 2013, WSI will utilize PMSI® d.b.a. tmesys®, to provide the same point-of-sale transactions currently in place with US Script®. Injured workers with an active claim have received an introduction letter including a temporary prescription card from tmesys®, with a permanent prescription card to be mailed in early November.

Key information to ensure prescriptions correctly process by tmesys® is:
BIN Number: 004261
PCN Number: CAL
ID Number: tmesys® claim number or 15 digit date of injury/SSN (yymmddssn)
**NOTE: A Group Number is no longer required for ND worker’s compensation prescriptions

Click here to view the notification letter sent to pharmacies regarding the change.

If you have questions about this article, please send an email to wsipr@nd.gov.

...
May 2013
Oxycontin Patent Protection

On April 17, 2013 Oxycontin was scheduled to go off the patent protection and become available for the generic marketplace. While WSI would generally welcome news of a highly utilized class of medications coming off patent, there were several concerns surrounding this particular generic formulation, specifically the potential for an increase in abuse and diversion.

Mindful of this, the FDA blocked the release of generic equivalents of the old formulations of Oxycontin. This is area in which the risk of abuse and diversion would have clearly outweighed any potential savings in drug spend for WSI.

Oxycontin was reformulated making the product more difficult to crush and/or dissolve. This also makes the product much more difficult to abuse, since the drug cannot be rapidly absorbed into the central nervous system and therefore does not lead to the sudden spikes in dopamine levels or rapid euphoria people are seeking.

The generic equivalents would have eliminated these safeguards. The action of the FDA should be applauded as allowing the generic formulations would have been a step backwards in the battle against prescription drug abuse.

For information on how providers and advocates can become more educated and engaged in the rise of prescription drug abuse, please visit the National Prescription Drug Abuse Summit homepage at http://nationalrxdrugabusesummit.org/

If you have questions about this article, please send an email to wsipr@nd.gov.

...
spacer image

Back to Top 

Employers | Workers | Medical Providers | Safety | Online Services | Fraud Awareness | Forms/Library 
Home | Contact Us | About Us | News | Careers | Calendar | Free e-Newsletter | Links | Site Map

© 2013 Workforce Safety & Insurance | comments: wsiwebmaster@nd.gov

Section 508 Accessibility Link    CSS Validation Link